Physical Confirmation and Mapping of Overlapping Rat Mammary Carcinoma Susceptibility QTLs, Mcs2 and Mcs6 by Sanders, Jennifer et al.
Physical Confirmation and Mapping of Overlapping Rat
Mammary Carcinoma Susceptibility QTLs, Mcs2 and Mcs6
Jennifer Sanders
1, Jill D. Haag
2, David J. Samuelson
1,3,4,5*
1Department of Biochemistry and Molecular Biology, University of Louisville School of Medicine, Louisville, Kentucky, United States of America, 2McArdle Laboratory for
Cancer Research, University of Wisconsin-Madison, Madison, Wisconsin, United States of America, 3James Graham Brown Cancer Center, University of Louisville School of
Medicine, Louisville, Kentucky, United States of America, 4Center for Genetics and Molecular Medicine, University of Louisville School of Medicine, Louisville, Kentucky,
United States of America, 5Center for Environmental Genomics and Integrative Biology, University of Louisville School of Medicine, Louisville, Kentucky, United States of
America
Abstract
Only a portion of the estimated heritability of breast cancer susceptibility has been explained by individual loci.
Comparative genetic approaches that first use an experimental organism to map susceptibility QTLs are unbiased methods
to identify human orthologs to target in human population-based genetic association studies. Here, overlapping rat
mammary carcinoma susceptibility (Mcs) predicted QTLs, Mcs6 and Mcs2, were physically confirmed and mapped to identify
the human orthologous region. To physically confirm Mcs6 and Mcs2, congenic lines were established using the Wistar-
Furth (WF) rat strain, which is susceptible to developing mammary carcinomas, as the recipient (genetic background) and
either Wistar-Kyoto (WKy, Mcs6) or Copenhagen (COP, Mcs2), which are resistant, as donor strains. By comparing Mcs
phenotypes of WF.WKy congenic lines with distinct segments of WKy chromosome 7 we physically confirmed and mapped
Mcs6 to ,33 Mb between markers D7Rat171 and gUwm64-3. The predicted Mcs2 QTL was also physically confirmed using
segments of COP chromosome 7 introgressed into a susceptible WF background. The Mcs6 and Mcs2 overlapping genomic
regions contain multiple annotated genes, but none have a clear or well established link to breast cancer susceptibility. Igf1
and Socs2 are two of multiple potential candidate genes in Mcs6. The human genomic region orthologous to rat Mcs6 is on
chromosome 12 from base positions 71,270,266 to 105,502,699. This region has not shown a genome-wide significant
association to breast cancer risk in pun studies of breast cancer susceptibility.
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Introduction
Breast cancer susceptibility is a complex trait controlled by genetic,
epigenetic, and environmental components. Susceptibility to breast
cancer is comprised of low, moderate, and high penetrance risk
alleles. Linkage analysis in high incidence families and population-
based genetic association studies using cases and controls have
identified breast cancer risk alleles; however, a large portion of the
estimated heritability in breast cancer susceptibility remains to be
explained [1,2]. Laboratory rats (Rattus norvegicus) have been used to
identify human breast cancer risk alleles using comparative genetics
[3]. To identify loci for comparative studies, rat strains that exhibited
phenotypic variation in susceptibility to chemical and hormone
induced mammary carcinogenesishave been used to predict mammary
carcinoma susceptibility (Mcs)a n destrogen-induced mammary cancer QTLs
[4]. Rats were chosen to identify Mcs QTLs because chemically
induced rat mammary carcinomas have similar histopathology to
human breast carcinomas [5]. The Wistar Furth (WF) rat strain is
susceptible to developing mammary carcinomas, while the Wistar
Kyoto (WKy) and Copenhagen (COP) rat strains are resistant [6,7].
A QTL linkage analysis of rat Mcs in females from [WF x WKY]F1 x
WF backcrosses predicted four Mcs QTLs named Mcs5, Mcs6, Mcs7,
and Mcs8 [7]. The Mcs6 QTL displayed a peak linkage at marker
D7Mit28 and significant linkage wasfound between markers D7Mit28
and D7Rat45. The predicted Mcs6 QTL region overlapped with
Mcs2, a Mcs QTL predicted using the mammary cancer resistant
Copenhagen (COP) rat strain [6]. The peak LOD score for the
predicted Mcs2 QTL was at genetic marker D7Uwm11. Here, we
physically confirm both Mcs2 and Mcs6 QTLs, and map Mcs6 to an
approximately 33 Mb region of rat chromosome 7,w h i c hi s
orthologous to a region on human chromosome 12.
Results
Congenics physically confirm and map Mcs6 to a 33Mb
region on rat chromosome 7
Figure 1 depicts the WF.WKy congenic lines used to physically
confirm and map the predicted Mcs6 QTL to a location on rat
chromosome 7 between markers D7Rat171 and gUwm64-3.T a b l e1
summarizes mammary carcinoma susceptibility (Mcs) phenotypes
from lines shown in Figure 1. Respectively, WF.WKy lines A, B, and
F had mammary carcinoma multiplicity phenotypes (mean 6 SD
carcinomas per rat) of 3.562.5, 3.962.6, and 3.462.1. These lines
developed significantly less mammary carcinomas compared to
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carcinomas per rat (Mann-Whitney test post hoc p-values=0.0012,
0.0007, and 0.0001). Females from WF.WKy lines A, B, and F had
similar mammary carcinoma multiplicity phenotypes when com-
pared to each other (Kruskal-Wallis test p-value=0.8171). WF.WKy
line C had a mean 6 SD of 8.064.1 mammary carcinomas per rat,
and line E had a mean 6 SD of 7.263.0. Neither line C nor line E
was significantly different from WF control animals (Mann-Whitney
test post hoc p-values=0.7521 and 0.7893, respectively). Decreased
susceptibility WF.WKy lines A, B, and F overlapped maximally from
markers D7Rat171 to D7Rat45, and minimally from gUwm64-24 to
gUwm64-3. We conclude that these lines physically confirm Mcs6 as
an independently acting Mcs QTL.
WF.WKy line C, which was not significantly different from
susceptible WF control animals, overlapped the distal end of the
Mcs6 region demarked by lines A, B, and F from markers gUwm64-3
to D7Rat128. This ruled out that this region contained Mcs6 or
independently acting susceptibility QTLs. The susceptible pheno-
type of line E, which partially overlapped susceptible line C,
confirmed that the region from gUwm64-12 to D7Rat128 did not
contain an independently acting Mcs QTL. When considered
together, our results from WF.WKycongenic lines delimited Mcs6to
a 33 Mb region of rat chromosome 7 from markers D7Rat171 to
gUwm64-3.
Mcs6 overlaps Mcs2 a Copenhagen rat QTL associated
with mammary cancer susceptibility
Mcs2 is a Copenhagen (COP) rat Mcs QTL that was also
predicted to reside on chromosome 7 [6]. The original QTL scans
of Mcs2 (COP) and Mcs6 (WKy) predicted regions of significant
linkage on rat chromosome 7 that overlapped from markers
D7Mgh15 to D7Mgh10 [7]. We physically confirmed Mcs2 using
WF.COP congenic lines A and B that each contained a COP
segment of rat chromosome 7 from markers D7rat39 to D7Uwm12
(Figure 1). These markers corresponded to rat chromosome 7 base
positions 4,936,704-86,028,057. WF.COP lines A and B had
similar mammary carcinoma multiplicity phenotypes of 2.461.6
and 2.061.5 mean 6 SD carcinomas per rat (Table 1, Mann-
Whitney test p-value 0.4510). Both lines were significantly less
than the WF susceptible phenotype (Mann-Whitney post hoc test p-
values ,0.0001). The confirmed Mcs2 QTL overlapped the
delimited Mcs6 QTL between markers D7Rat171 and gUwm64-3
(Figure 1). The pooled phenotypes of Mcs2 (WF.COP lines A and
B) and Mcs6 (WF.WKy lines A, B, and F) females were,
respectively, 2.261.5 and 3.662.4 mean 6 SD mammary
carcinomas per rat. These phenotypic values were statistically
different (Mann-Whitney test p-value=0.0030) suggesting that the
Mcs2 COP allele may have additional genetic variation contribut-
ing to mammary carcinoma resistance.
The human ortholog to rat Mcs6 is on chromosome 12
Using the UCSC rat and human genome browsers (geno-
me.ucsc.edu) we determined that the Mcs6 QTL from markers
D7Rat171 to gUwm64-3 (chr7:22,382,725-55,364,398) aligns to a
contiguous 34.2 Mb region of human chromosome 12 from base
positions 71,299,117 to 105,502,699, which was inverted with
respect to the rat genome assembly. Within these orthologous
regions 37.7% of the bases over 99.9% of the span were identical.
Rat genomic sequence flanking Mcs6 aligned to human chromo-
some 12 up to rat chromosome 7 base positions 22,310,240 on one
flank and 55,442,351 on the other flank. Moving out past these
syntenic regions of rat chromosome 7 and human chromosome 12
resulted in rat genomic sequence that aligned to human chromo-
some 16 on one flank and chromosome X on the other.
Figure 1. Congenic lines used to physically confirm Mcs6 and
Mcs2 QTLs and map the Mcs6 locus to ,33 Mb on rat
chromosome 7. Informative genetic markers between WF and WKy
rat strains used in the genotyping of WF.WKy chromosome 7 lines are
shown on the right of the y-axis, which represents the region of rat
chromosome 7 that contains Mcs6. Congenic lines were established
using genetic marker genotype selection and backcrossing to WF
homozygous females, which was followed by brother-sister mating to
fix homozygous congenic lines in the chromosomal segments shown.
Superscript letters indicate which line the respective superscripted line
was derived from. WF.WKy chromosome 7 lines A, B, and F (red bars) all
showed a statistically significant decrease in mean tumor number
compared to WF control females (respective Mann-Whitney post hoc p-
values were=0.0012, 0.0007, and 0.0001), while lines C and E (yellow
bars) were not significantly different from the susceptible WF
phenotype (Mann-Whitney post hoc p-values=0.7521and 0.7893,
respectively). The gray bars at the ends of congenic line segments
denote regions of unknown genotype. WF.COP chromosome 7 Mcs2
congenic lines A and B that physically confirm the Mcs2 QTL and
overlap the Mcs6 QTL are shown with brown bars that represent the
segment of COP chromosome 7 contained in each line. The arrows at
the end of Mcs2 congenic line segments indicate that the COP
chromosome 7 segment continues off this map. WF.COP chromosome 7
Mcs2 lines A and B developed significantly less mammary carcinomas
than WF control females (Mann-Whitney post hoc p-values ,0.0001).
doi:10.1371/journal.pone.0019891.g001
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markers D7Rat171 and gUwm64-3. These genes were on the UCS-
C rat November 2004 assembly (build 3.4/rn4). Not including
pseudogenes, this region contained 111 annotated genes including
two microRNAs (Mir135 and Mir331). There were 137 annotated
genes found in Mcs6 using the Rat Genome Database (rgd.mcw.-
edu), and 215 found using the Ensembl Genome Browser
(uswest.ensembl.org) rat database. Independent searches of Mcs6
potential candidate genes using gene ontology terms limited to
mammary, hormone, estradiol, or DNA repair resulted in the
following gene list: S o c s 2 ,I g f 1 ,N r 1 h 4 ,O s b p l 8 ,N r 2 c 1 ,P m c h ,S t a b 2 ,N t s ,
Lgr5, Btg1, Lta4h, and Ube2n. All genes located in rat Mcs6 were also
annotated in the human orthologous region. There were a total of
243 genes listed in the human orthologous region when the UCSC
human genome browser was queried and 226 genes when the
Ensembl browser was used.
We queried the Oncomine 4.4 database (www.oncomine.org,
Compendia Bioscience) to identify Mcs6 human orthologs that
may have been reported as differentially expressed between non-
diseased breast tissue and ductal breast carcinomas. A list of the
studies included can be found in References S1 (S1-S7). Results
from this search are presented in Table S1. There were twenty-
nine transcripts reported with p-values ,0.05, and six of these had
p-values ,0.001 Mcs6 human orthologs with p-values ,0.001
were ALX1, DUSP6, EPYC, PPP1R12A, TXNRD1, and ZDHHC17.
To determine if genetic variation in the Mcs6 orthologous hu-
man genomic region from chromosome 12:71,270,266-105,-
502,699 might be associated with breast cancer susceptibility we
searched the NCBI dbGAP database using the association results
browser set to ‘‘breast neoplasms’’ and chromosome 12 (www.ncbi.
nlm.nih.gov/gap). We also searched published breast cancer risk
GWA studies for positive associations in this region. A list of the
association studies included can be found in References S1 (S8-S23).
While five human SNPs were identified that potentially associated
with breast cancer susceptibility, tested genetic variants did not reach
a genome-wide significance level of P, 10
-7 proposed by Thomas
et al. [8]. A summary of human SNPs in the Mcs6 orthologous region
that potentially associate with breast cancer risk can be found in
Table S2.
Discussion
Both mammary cancer susceptibility QTL mapping in rats and
low-penetrance breast cancer risk associated allele identification in
humans are in early stages of discovery. Results of human
population-based and rat genetic studies completed to date
indicate that a majority of breast cancer risk alleles are low-
penetrance, and pathways in addition to DNA repair and
hormonal regulation control susceptibility. Furthermore, a major-
ity of the risk associated polymorphisms that have been identified
reside in non-protein coding DNA. Given the commonalities of
low-penetrance, novel pathways, and non-protein-coding risk
alleles, it is possible that there is some degree of overlap in
susceptibility loci between these two organisms. There may be
shared susceptibility loci that can be more easily identified in rats
than by current human GWAS methods. If this is the case,
resolving rat mammary carcinoma susceptibility QTLs to single
loci so that the human orthologs can be extensively tested in
human population-based genome-targeted association studies may
continue to be fruitful. This was the case for Gould and colleagues
who used rat Mcs5a to successfully target the orthologous human
genomic region to identify two breast cancer susceptibility alleles
on human chromosome 9 [3]. Quan et al. have shown that rodent
susceptibility QTLs identified for a specific tumor type may also be
useful to identify common susceptibility alleles for other tumor
types [9]. Thus, the amount of overlap between rodent and human
common disease susceptibility loci may be appreciable.
Here, predicted rat mammary carcinoma susceptibility QTLs
Mcs6 and Mcs2 were physically confirmed using congenics. In our
study Mcs2 and Mcs6, respectively, reduced the mammary
carcinoma susceptibility phenotype of the WF strain by 70 and
50% when homozygous. In the original QTL studies, one Mcs2
COP or one Mcs6 WKy allele was predicted to reduce tumor
multiplicity by 43% or 40%, respectively [6,7]. While those studies
were not completed using congenics, and we have not tested
heterozygous females, comparing the results of tumor numbers of
homozygous Mcs2 and Mcs6 congenics with heterozygous females
from the previous studies suggests there may be some degree of
dominance from the WF allele at this locus. However, these
differences may also be explained by background COP and WKy
alleles that would have been present in females used for the QTL
linkage studies. The stronger effect of the Mcs2 COP allele
compared to the Mcs6 WKy allele may indicate that the
Copenhagen strain has additional genetic variation within the
region that contributes to reducing the Mcs phenotype.
In this study Mcs6 was mapped to a 33 Mb region from markers
D7Rat171 to gUwm64-3, which corresponds to rat chromosome 7
base positions 22,382,725-55,364,398. The peak LOD scores for
genetic markers in the predicted Mcs6 and Mcs2 QTLs were at
D7Mit28 and D7Uwm11, respectively [6,7]. Both peak QTL
markers fall within the narrowed interval confirmed here with
Table 1. Summary of mammary carcinoma multiplicity phenotypes from WF.WKy and WF.COP rat chromosome 7 congenic lines
used to map Mcs6 and Mcs2.
WF.WKy Congenic Line WF.COP Congenic Line
AB C EFABW F
Congenic Region
1
Marker/Marker
D7Rat171/
D7Rat128
D7Rat171/
D7Rat128
D7Rat51/
D7Rat128
gUwm64-12/
D7Rat128
D7Rat171/
D7Rat45
D7rat39/
D7Uwm12
D7rat39/
D7Uwm12
-
Mean (SD) Mammary
Carcinomas per Rat
3.5 (2.5) 3.9 (2.6) 8.0 (4.1) 7.2 (3.0) 3.4 (2.1) 2.4 (1.6) 2.0 (1.5) 7.3 (3.6)
N 17 32 23 43 28 16 16 19
p-value
2 0.0012 0.0007 0.7521 0.7893 0.0001 ,0.0001 ,0.0001 -
1Markers spanning the maximal WKy or COP Chr 7 segment that was introgressed onto a susceptible WF genetic background are given.
2p-values are from Mann-Whitney nonparametric post hoc tests comparing each congenic line to the WF phenotype after a statistically significant Kruskal-Wallis test
with a p-value ,0.0001.
doi:10.1371/journal.pone.0019891.t001
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D7Uwm11 is at base position Chr7:50,160,469. This supports
using QTL linkage analysis of rat complex phenotypes to identify
regions of the genome on which to focus targeted human genome
association studies.
Alignment of the rat Mcs6 QTL region to the human genome
reference sequence revealed that the human orthologous region is
entirely positioned on 34.2 Mb of chromosome 12, and is inverted
compared to rat Mcs6. To our knowledge no polymorphisms in the
human genome region orthologous to rat Mcs6 have shown a
genome-wide significant association to breast cancer risk in a
GWAS. An intriguing potential candidate gene in Mcs6 is insulin-
like growth factor 1 (Igf1). Human candidate-gene association studies
that have tested IGF1 locus polymorphisms reported mixed results
ranging from significant low-penetrance to null associations
between IGF1 alleles and breast cancer risk [10–15]. Increased
IGF1 levels have been associated with breast cancer and increased
breast cancer susceptibility [16,17]. Common genetic variation in
IGF1 has been associated with circulating levels of IGF1 in a
population-based study [15]. Other Mcs6 potential candidates
have human orthologs that have been associated with cancer or
other human diseases. SLC5A8 and GLIPR1 are predicted tumor
repressor genes [18,19]. METAP2 is predicted to be anti-
angiogenic [20]. A human genome-wide linkage analysis of
posterior amorphous corneal dystrophy identified a region of
human chromosome 12 that is orthologous to a Mcs6 region that
contains genes DCN, LUM, KERA, and EPYC [21]. PCTK2 has
been shown to be upregulated in sporadic breast cancer biopsies in
women of Mexican ancestry [22]. Suppressor of cytokine signaling 2
(Socs2) is also a promising potential candidate gene in Mcs6. Higher
Figure 2. Transcript map of the delimited rat Mcs6 QTL. Map of the Mcs6 locus showing known and predicted transcripts in the Mcs6 region
that were annotated on the UCSC Rat Nov. 2004 (Baylor3.4/rn4) Genome Browser. The x-axis represents rat chromosome 7 from genetic markers
D7Rat171 to gUwm64-3; a rat chromosome 7 region from bp 22,382,725-55,364,398 that contains Mcs6. The dashed vertical lines demark the
respective maximal and minimal rat genomic regions that contain Mcs6. Transcripts are shown by NCBI gene symbol at approximate genomic
positions within Mcs6. Genetic markers within the region are shown as labeled tick marks on the x-axis. WF.WKy chromosome 7 lines F (red horizontal
bar, resistant Mcs phenotype) and C (yellow horizontal bar, susceptible Mcs phenotype) are included to serve as reference points. The gray horizontal
bars at the ends of congenic lines denote a segment of unknown genotype for the respective line.
doi:10.1371/journal.pone.0019891.g002
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prognosis [23–25]. Socs2 is an important mediator of prolactin
regulated mammary gland development in the mouse [26]. SOCS2
is upregulated by 17b-estradiol in cancer cell lines [27], and
SOCS2 expression was found to be higher in breast carcinomas
compared to non-diseased breast tissue [28].
Mcs6 human orthologous transcripts that have been reported as
differentially expressed between non-diseased breast tissue and
ductal carcinoma tissue encode for two phosphatases (DUSP6,
PPP1R12A), a proteoglycan (EPYC), a redox regulator (TXNR-
D1), and two uncharacterized proteins (ALX1, ZDHHC17).
These findings suggest that the rat Mcs2 and Mcs6 QTLs control
potentially novel mechanisms contributing to mammary cancer
susceptibility that could translate to breast cancer.
Human genetic variation in the Mcs6 orthologous genomic
region has been reported to be associated with breast cancer
susceptibility, but tested polymorphisms have not reached
genome-wide level significance. This highlights the importance
of this region to breast cancer genetics. It suggests, as many have,
that Bonferroni correction based methods may be too stringent to
control for multiple comparison testing in human population-
based association studies. The confirmed rat Mcs2 and Mcs6 QTLs
support that some or all of the potential human breast cancer risk
associations are true positives and warrant further investigation.
We conclude that the human genomic region on chromosome
12 from base positions 71,270,266 - 105,502,699 is orthologous to
rat Mcs6. This region may be a good target for extensive
population-based genetic association studies to determine if
humans have a concordant breast cancer susceptibility allele.
Rat Mcs6 and Mcs2 congenic lines will be useful to study breast
cancer genetic susceptibility mechanisms.
Materials and Methods
Congenic Breeding and Genotyping
Congenic lines were established using previously described
methods [29] and are defined as rats with specified WKy
chromosome 7 segments from the predicted Mcs6 QTL or the
specified COP chromosome 7 segments from the predicted Mcs2
QTL introgressed into a WF genetic background. Rats were
housed in an AALACC approved facility and protocols were
approved by a University of Louisville institutional animal care
and use committee under protocol number 07118. Genotyping
was performed at the markers shown in Figure 1 according to
methods previously described [29]. Primer and sequence informa-
tion for most genetic markers used is available at the Rat Genome
Database (rgd.mcw.edu) [30]. The following primer sequence
pairs are for genetic markers that were submitted to the NCBI
probe database, but may not yet be publicly available: gUwm64-24,
59-TGTCCTCTCATACCACTTCC-39,5 9-CGGT-
GGTCATACTCTGAAT-39; gUwm64-3,5 9-AACAGTTCTCC-
TTTCCCTTC-39,5 9-TCTCTTTGCCAGTCTGTTTT-39, gU-
wm64-12, 59-CTGGTCATTCAACAGGAAAT-39,5 9-CCTAT-
CCCTGTTCTTCCTCT-39; and gUwm64-19, 59-AACAATAG-
GCACAGTGAT-39,5 9-ATGCTGTCAGAACGGTAAGT-39.
Phenotyping
Female congenic and WF (Harlan) rats at 50-55 days of age were
treated with a single dose of 7,12-Dimethylbenz(a)anthracene
(DMBA, ACROS Organics, Fisher Scientific) in sesame oil by gastric
intubation at 65 mg DMBA/kg body mass. Mammary carcinomas
$363m m
2 were counted at 15 weeks following DMBA treatment.
Mammary carcinoma multiplicity data were analyzed to compare
congenic line phenotypes to susceptible WF control females.
WF.WKy chromosome 7 congenic phenotypes for each line were
from the following generations: line A, N11F2 and N11F4 (total
n=17); line B, N11F2 and N11F3 (total n=32); line C, N14F2,
N14F3, and N14F4 (total n=23); line E, N14F2 and N14F4 (total
n=43); and line F, N14F3 and N14F4 (total n=28). WF.COP
chromosome 7 congenic phenotypes were from generations: line A,
N10F5 (n=16); and line B, N11F3 and N11F4 (total n=16).
Statistical analysis
To compare mammary carcinoma susceptibility phenotypes,
mammary carcinoma multiplicity data were analyzed using
Statview (SAS Institute). Mammary carcinoma multiplicity
phenotypes for more than two groups were compared using the
Kruskal-Wallis nonparametric test. If this test was statistically
significant (p value ,0.05) multiple Mann-Whitney nonparametric
tests were performed by comparing each congenic line phenotype
to the susceptible WF control group. To correct for multiple
comparisons a p-value #0.007 (a=0.05/7 comparisons) was
required for statistical significance. For analysis of two groups,
Mann-Whitney nonparametric tests were performed and p-values
#0.05 were required for statistical significance.
Bioinformatics
Identification of the human orthologous region and transcripts
mapping to human and rat regions of interest were performed
using the RGD, UCSC, and Ensembl genome browsers [30-32].
The genome assemblies used were Homo sapiens version GRCh37/
hg19 and Rattus norvegicus version 3.4/rn4. The percent sequence
identity between human and rat was determined using the
‘‘Convert’’ option at the UCSC Genome Browser. The gene
ontology search was completed by downloading from the Rat
Genome Database gene ontology terms for genes annotated in
Mcs6 and searching this database by terms: ‘‘mammary’’,
‘‘hormone’’, ‘‘estradiol’’, or ‘‘DNA repair’’.
Supporting Information
Table S1 Results of a query using Oncomine to identify human
Mcs6 orthologous transcripts that have been shown to be
differentially expressed between non-diseased and ductal carci-
noma breast tissues.
(DOCX)
Table S2 Human polymorphisms located in the Mcs6 ortholo-
gous region that have not reached genome-wide significance, but
are potentially associated with breast cancer susceptibility.
(DOCX)
References S1 Citations for supplemental references.
(DOCX)
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